Crossmatch and HLA Testing Before Transplant: What Results Mean

Crossmatch and HLA testing are key steps before many organ and stem cell transplants. These tests help transplant teams understand how compatible a donor and recipient are and how to reduce the risk of rejection.

Overview

Before a transplant, doctors need to know how the recipient’s immune system may react to the donor organ, tissue or stem cells. Crossmatch and HLA testing are laboratory tests used to assess this compatibility. They do not predict the future perfectly, but they provide important information about the likelihood of an immune reaction and help guide safe transplant planning.

HLA stands for human leukocyte antigen. HLAs are proteins found on the surface of many cells in the body. They act like identity markers for the immune system. When the immune system detects cells with HLA patterns it sees as foreign, it may produce antibodies or activate immune cells to attack them. This response is helpful against infections, but it can also contribute to transplant rejection.

Crossmatch testing looks for antibodies in the recipient’s blood that react with the donor’s cells or HLA markers. In many transplants, especially kidney, heart, lung and some other solid organ transplants, this test helps identify donor-specific antibodies before surgery. In stem cell transplantation, HLA matching is also central because the donor immune cells can react against the recipient’s tissues, a complication known as graft-versus-host disease.

What HLA Testing Shows

HLA testing, sometimes called HLA typing, identifies a person’s HLA pattern. The most important HLA groups vary by transplant type, but commonly include HLA-A, HLA-B, HLA-C, HLA-DR, HLA-DQ and HLA-DP. These markers are inherited from both parents, which is why siblings sometimes have close matches and unrelated people may have partial matches.

For kidney transplantation, closer HLA matching can improve long-term compatibility, although excellent outcomes are possible with less-than-perfect matches when modern immunosuppressive treatment is used. For liver transplantation, HLA matching is usually less central than for kidney or stem cell transplantation because the liver is often more immunologically tolerant. For hematopoietic stem cell transplantation, a close HLA match is usually very important to reduce the risk of graft rejection and graft-versus-host disease.

HLA results are not judged simply as good or bad. A transplant team considers the number and importance of matched markers, the recipient’s antibody profile, the donor type, urgency, organ availability and the recipient’s overall condition. A person may be an acceptable candidate with several HLA differences if crossmatch and antibody testing are reassuring.

Antibody Screening and Sensitization

In addition to HLA typing, many patients have antibody screening. This test checks whether the recipient has antibodies against HLA markers commonly found in the population. Antibodies can develop after exposure to another person’s cells or tissues, and they may remain in the blood for a long time.

Common reasons a person may become sensitized include previous transplantation, blood transfusions and pregnancy. Some people have a high level of sensitization, meaning they have antibodies against many possible donors. This can make it harder to find a compatible donor, but it does not mean transplant is impossible. It means the search and planning may need to be more detailed.

Laboratories may report antibody findings using terms such as PRA or cPRA, which estimate how broadly a patient may react to potential donors. They may also identify donor-specific antibodies, often shortened to DSA. Donor-specific antibodies are particularly important because they are directed against the actual donor being considered.

Crossmatch Testing: Types and Results

A crossmatch test compares the recipient’s blood serum with donor cells or donor HLA information. The goal is to see whether antibodies in the recipient’s blood recognize and bind to the donor. A negative crossmatch generally means no significant reaction was detected in that test, which is usually a favorable finding for proceeding with transplant evaluation.

A positive crossmatch means the test detected an antibody reaction against the donor. This may increase the risk of antibody-mediated rejection, especially in kidney and some other solid organ transplants. However, the meaning depends on the strength of the reaction, the type of antibody, the transplant being planned and the patient’s clinical situation. Some positive results are considered too risky, while others may be managed with careful planning.

There are different crossmatch methods. Complement-dependent cytotoxicity crossmatch is an older method that detects antibodies capable of damaging donor cells in the laboratory. Flow cytometry crossmatch is more sensitive and can detect lower levels of antibodies. Virtual crossmatch uses HLA typing and antibody test data to predict compatibility without mixing blood and cells in the same way. Transplant teams may use one or more of these methods depending on the case and local protocols.

What Results May Mean for the Transplant Plan

Test results help the transplant team decide whether a donor is suitable, whether more tests are needed and what precautions may be appropriate. A negative crossmatch with no concerning donor-specific antibodies is often reassuring, but it is not the only requirement. The donor organ or cells must also be medically suitable, and the recipient must be fit enough for the procedure and follow-up care.

If HLA matching is less close but the crossmatch is negative, transplantation may still be considered, especially for many solid organ transplants. The team may adjust immunosuppressive treatment, monitor antibodies after transplant or schedule closer follow-up. In stem cell transplantation, a less-than-perfect HLA match may require special donor selection strategies and preventive treatment to lower immune complications.

If a positive crossmatch or strong donor-specific antibody is found, possible next steps may include:

• Choosing a different donor if one is available.
• Repeating or confirming the test to understand the result more clearly.
• Considering desensitization treatment in selected cases to reduce antibody levels.
• Using paired donation or exchange programs for some kidney transplant candidates.
• Proceeding only if the expected benefits outweigh the immunologic risks.

These decisions are individualized. A result that is acceptable in one clinical situation may not be acceptable in another. Patients should ask their transplant team to explain their results in relation to their own transplant type and medical history.

How Patients Can Prepare for Testing

Crossmatch and HLA testing usually require a blood sample. Patients may be asked about previous transfusions, pregnancies, infections, vaccinations, previous transplants and recent treatments because these can affect antibody results or timing. It is important to share a complete medical history, including care received in other countries or hospitals.

Patients should also tell the transplant team if they recently received blood products or had a major immune event, such as a serious infection. Antibody levels can change over time, so repeat testing may be needed while waiting for a transplant or before a planned living donor procedure. This is normal and helps keep the compatibility assessment current.

For living donor transplantation, the donor and recipient may both have HLA typing and crossmatch testing early in the evaluation. For deceased donor transplantation, some testing must happen quickly when an organ becomes available. A transplant center may use stored blood samples, recent antibody results and virtual crossmatch methods to support timely decisions.

Prevention, Follow-Up and Reducing Risk

Patients cannot change their HLA type, and antibody history cannot always be prevented. However, certain steps can help reduce avoidable sensitization and support safer transplant planning. For example, blood transfusions are used when medically necessary, but doctors may consider transplant plans when deciding how to manage anemia or bleeding in patients waiting for transplant.

After transplant, immune monitoring continues. Some patients have periodic antibody testing, kidney function tests, biopsies or imaging depending on the transplant type. Taking immunosuppressive medicines exactly as prescribed is one of the most important ways to reduce rejection risk. Patients should never stop or change these medicines without their transplant doctor’s guidance.

Healthy self-care also supports transplant outcomes. Patients are usually advised to attend all follow-up visits, report fever or new symptoms promptly, follow infection-prevention advice and keep an updated medication list. The transplant team can explain which warning signs matter most for the specific organ or cell transplant involved.

When to Speak With a Transplant Specialist

Patients should speak with their transplant specialist whenever they do not understand a crossmatch, HLA or antibody result. It is reasonable to ask whether a crossmatch was negative or positive, whether donor-specific antibodies were detected, how strong the antibodies are and how the results affect donor choice. Clear communication helps patients and families participate in decisions with confidence.

A specialist review is especially important if a patient has had previous transplants, multiple transfusions, pregnancies, a high cPRA or a history of rejection. These factors can make compatibility planning more complex. The team may involve transplant surgeons, nephrologists, hematologists, immunologists, tissue-typing laboratory experts and other specialists depending on the transplant type.

For international patients seeking evaluation, Acibadem International’s multidisciplinary specialists and JCI-accredited hospitals diagnose and treat transplant-related conditions, including compatibility assessment, as part of individualized care planning. Patients should bring prior test reports, medication lists and transplant records to help the team interpret results accurately.

Frequently asked questions

What is the difference between HLA testing and crossmatch testing?

HLA testing identifies the immune markers carried by the donor and recipient. Crossmatch testing checks whether the recipient has antibodies that react against the donor. Both tests are used together to understand compatibility and rejection risk.

Does a negative crossmatch mean the transplant will definitely succeed?

A negative crossmatch is generally a reassuring result, but it does not guarantee success. Transplant outcomes also depend on the quality of the donor organ or cells, the recipient's health, surgery, medicines, infections and long-term follow-up.

Does a positive crossmatch mean transplant is impossible?

Not always. A positive crossmatch may increase the risk of rejection, but the level of risk depends on the antibody type, strength and transplant situation. The team may look for another donor, repeat testing or consider special treatment in selected cases.

Why do pregnancy, transfusion or previous transplant matter?

These events can expose the immune system to another person's HLA markers. In response, the body may form antibodies that remain detectable for years. Those antibodies can affect compatibility with future donors.

Can HLA antibodies change over time?

Yes. Antibody levels can rise or fall, and new antibodies can appear after immune exposure. This is why patients on a transplant waiting list may need regular blood samples and updated antibody screening.

Is HLA matching equally important for every transplant?

No. HLA matching is very important in stem cell transplantation and often important in kidney transplantation. It may be less central in some other solid organ transplants, such as liver transplant, where other clinical factors may carry more weight.

What should patients ask their doctor about their results?

Patients can ask whether donor-specific antibodies were found, whether the crossmatch was negative or positive, and how these results affect the donor choice. They should also ask whether repeat testing, extra monitoring or special treatment is recommended.

References

• American Society of Transplantation
• National Kidney Foundation
• Organ Procurement and Transplantation Network
• British Society for Histocompatibility and Immunogenetics
• European Society for Blood and Marrow Transplantation

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.